Cue Biopharma (CUE)
(Delayed Data from NSDQ)
$0.72 USD
+0.02 (3.00%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $0.72 0.00 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CUE 0.72 +0.02(3.00%)
Will CUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CUE
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
CUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Xoma (XOMA) Soars 15.6%: Is Further Upside Left in the Stock?
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
Other News for CUE
Cue Energy Complies with Governance Standards
Cue Energy Announces Solid Year-End Dividends
Cue Energy Confirms Dividend for September 2024
Cue Energy Announces Financial Results and Dividends
Cue Biopharma Inc (CUE) Q2 2024 Earnings Call Transcript Highlights: Clinical Successes and ...